Showing results (201-210 of 355) with videos related to
Sort By:
Pageof 36
Circulation. Cardiovascular Quality and Outcomes|August 31, 2024
Relative Effectiveness of High-Dose Versus Standard-Dose Quadrivalent Influenza Vaccine in Older Adults With Cardiovascular Disease: A Prespecified Analysis of the DANFLU-1 Randomized Clinical TrialJacob Christensen, Niklas Dyrby Johansen, Daniel Modin, et al.European Journal of Heart Failure|April 11, 2025
Finerenone, glycaemic status, and heart failure with mildly reduced or preserved ejection fraction: A prespecified analysis of the FINEARTS-HF trialJawad H Butt, Pardeep S Jhund, Alasdair D Henderson, et al.Circulation|September 1, 2024
Therapeutic Effects of Heart Failure Medical Therapies on Standardized Kidney Outcomes: Comprehensive Individual Participant-Level Analysis of 6 Randomized Clinical TrialsJawad H Butt, John J V McMurray, Brian L Claggett, et al.Clinical Journal of the American Society of Nephrology : CJASN|January 2, 2026
Finerenone and eGFR slope across Different Levels of Baseline Albuminuria and Estimated Glomerular Filtration Rate: Insights from FINEARTS-HFFinnian R Mc Causland, Hiddo J L Heerspink, Muthiah Vaduganathan, et al.Hypertension (Dallas, Tex. : 1979)|December 4, 2023
Cardiac Abnormalities in Hispanic/Latina Women With Prior De Novo Hypertensive Disorders of PregnancyOdayme Quesada, Shathiyah Kulandavelu, Catherine J Vladutiu, et al.Journal of the American College of Cardiology|October 1, 2024
Finerenone in Patients With a Recent Worsening Heart Failure Event: The FINEARTS-HF TrialAkshay S Desai, Muthiah Vaduganathan, Brian L Claggett, et al.European Journal of Heart Failure|September 20, 2024
In-hospital course of patients with heart failure with improved ejection fraction in the DELIVER trialMaria A Pabon, Muthiah Vaduganathan, Brian L Claggett, et al.Journal of the American College of Cardiology|November 3, 2024
Finerenone and Kidney Outcomes in Patients With Heart Failure: The FINEARTS-HF TrialFinnian R Mc Causland, Muthiah Vaduganathan, Brian L Claggett, et al.JACC. Heart Failure|September 16, 2022
Influence of NT-proBNP on Efficacy of Dapagliflozin in Heart Failure With Mildly Reduced or Preserved Ejection FractionPeder L Myhre, Muthiah Vaduganathan, Brian L Claggett, et al.European Journal of Heart Failure|August 26, 2023
Influence of background medical therapy on efficacy and safety of dapagliflozin in patients with heart failure with improved ejection fraction in the DELIVER trialMaria Pabon, Brian L Claggett, Xiaowen Wang, et al.Pageof 36